OncoSec Medical Incorporated

Equities

ONCSQ

US68234L4059

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 02:15:21 2024-05-29 pm EDT			5-day change	1st Jan Change
0.0001 ^USD	+9,900.00%		-.--%	-.--%

2023	Motion for Asset Sale Approved for OncoSec Medical Incorporated	CI
2023	Motion for Asset Sale Filed by OncoSec Medical Incorporated	CI

OncoSec Medical Incorporated Reports Earnings Results for the Second Quarter and Six Months Ended January 31, 2022

March 15, 2022 at 04:16 pm EDT

OncoSec Medical Incorporated reported earnings results for the second quarter and six months ended January 31, 2022. For the second quarter, the company reported net loss was USD 9.91 million compared to USD 10.7 million a year ago. Basic loss per share from continuing operations was USD 5.5 compared to USD 8.14 a year ago.
For the six months, net loss was USD 19.72 million compared to USD 23.93 million a year ago. Basic loss per share from continuing operations was USD 11 compared to USD 18.92 a year ago.

Latest news about OncoSec Medical Incorporated

Motion for Asset Sale Approved for OncoSec Medical Incorporated	23-08-09	CI
Motion for Asset Sale Filed by OncoSec Medical Incorporated	23-07-28	CI
OncoSec Medical Incorporated(NasdaqCM:ONCS) dropped from S&P TMI Index	23-06-28	CI
Wall Street Set to Open Lower Ahead of June's Flash PMI; Oil Prices Drop Sharply	23-06-23	MT
US Futures Trend Lower Premarket Friday Ahead of June's Flash PMI	23-06-23	MT
Top Premarket Gainers	23-06-23	MT
OncoSec Medical Incorporated(OTCPK:ONCS.Q) dropped from NASDAQ Composite Index	23-06-23	CI
Certain Stock Options of OncoSec Medical Incorporated are subject to a Lock-Up Agreement Ending on 18-JUN-2023.	23-06-17	CI
Certain Common Stock of OncoSec Medical Incorporated are subject to a Lock-Up Agreement Ending on 18-JUN-2023.	23-06-17	CI
Certain Promissory Notes of OncoSec Medical Incorporated are subject to a Lock-Up Agreement Ending on 18-JUN-2023.	23-06-17	CI
Certain Warrants of OncoSec Medical Incorporated are subject to a Lock-Up Agreement Ending on 18-JUN-2023.	23-06-17	CI
OncoSec Medical Incorporated Announces Resignation of Dr. Robert Arch as Chief Executive Officer	23-06-14	CI
OncoSec Medical Incorporated Announces Management Resignations	23-06-14	CI
OncoSec Medical Incorporated Announces Termination of George Chi as Chief Financial Officer	23-06-14	CI
OncoSec Medical Incorporated Filed for Bankruptcy	23-06-14	CI
OncoSec Medical Closes $1.3 Million Registered Direct Offering	23-05-19	MT
Oncosec Medical Incorporated Announces Type C Meeting with the US Food and Drug Administration to Discuss Proposed Neoadjuvant Melanoma Clinical Program	23-05-16	CI
OncoSec Medical Launches $2 Million Registered Direct Offering; Shares Surge	23-04-10	MT
Sector Update: Health Care Stocks Higher Late Monday	23-04-03	MT
Top Midday Decliners	23-04-03	MT
Surging Oil Prices Trigger Fresh Inflation Worries, Driving Mixed Premarket Trading for US Equity Futures	23-04-03	MT
Top Premarket Decliners	23-04-03	MT
OncoSec Medical Announces Clinical Data of the KEYNOTE-695 Trial Assessing TAVO-EP in Combination with KEYTRUDA (pembrolizumab) in Patients with Advanced Melanoma Refractory to Anti-PD-1 Treatment	23-04-03	CI
Top Premarket Decliners	23-03-28	MT
OncoSec Medical Incorporated Reports Earnings Results for the Second Quarter and Six Months Ended January 31, 2023	23-03-14	CI

Chart OncoSec Medical Incorporated

Duration

Period

More charts

Company Profile

OncoSec Medical Incorporated is a late-stage immuno-oncology company. The Company is focused on designing, developing and commercializing intra-tumoral DNA-based therapeutics delivered by electroporation (EP) to stimulate and augment anti-tumor immune responses for the treatment of cancers. Its core technology, ImmunoPulse, is a drug-device therapeutic modality platform comprised of an OncoSec Medical System EP device (the OMS EP Device) and a DNA plasmid delivery and application method that enables transient expression of recombinant therapeutic molecules in cells. The OMS EP Device is designed to promote cellular uptake of plasmid DNA injected directly into solid tumors to allow subsequent expression of the encoded therapeutic protein. The OMS EP Device can be adapted to treat different tumor types and consists of an electrical pulse generator and a disposable applicator. Its lead product candidate, tavokinogene telseplasmid (TAVO), is a plasmid encoding human interleukin-12.

Sector

Biotechnology & Medical Research

Calendar

2025-03-11 - Q2 2025 Earnings Release (Projected)

More about the company

	1st Jan change	Capi.
ONCOSEC MEDICAL INCORPORATED	-.--%	596
MODERNA, INC.	+43.36%	54.63B
IQVIA HOLDINGS INC.	-5.31%	39.92B
ICON PUBLIC LIMITED COMPANY	+14.75%	26.86B
CELLTRION, INC.	-12.56%	26.22B
ALNYLAM PHARMACEUTICALS, INC.	-22.45%	18.78B
UNITED THERAPEUTICS CORPORATION	+25.12%	12.21B
BIO-TECHNE CORPORATION	+0.04%	12.16B
MEDPACE HOLDINGS, INC.	+26.04%	11.94B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-11.83%	10.74B

Other Biotechnology & Medical Research